Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014165701 - APPLICATION OF 5-HT6 RECEPTOR ANTAGONISTS FOR THE ALLEVIATION OF COGNITIVE DEFICITS OF DOWN SYNDROME

Publication Number WO/2014/165701
Publication Date 09.10.2014
International Application No. PCT/US2014/032876
International Filing Date 03.04.2014
IPC
A61P 25/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CPC
A61K 31/165
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/27
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
27of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
A61K 31/4045
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
A61K 31/407
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/4425
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
Applicants
  • THE UNIVERSITY OF UTAH RESEARCH FOUNDATION [US]/[US]
Inventors
  • KORENBERG, Julie Ruth
  • WILCOX, Karen Sue
  • WEST, Peter Jeffrey
  • KESNER, Raymond Pierre
Agents
  • YEE, Gene
Priority Data
61/808,19603.04.2013US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) APPLICATION OF 5-HT6 RECEPTOR ANTAGONISTS FOR THE ALLEVIATION OF COGNITIVE DEFICITS OF DOWN SYNDROME
(FR) APPLICATION D'ANTAGONISTES DU RÉCEPTEUR 5-HT6 POUR L'ATTÉNUATION DE DÉFICITS COGNITIFS DU SYNDROME DE DOWN
Abstract
(EN)
Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-HT 6) receptor antagonists are provided for improving the cognition of a Down syndrome patient. Through the use of a mouse model of DS, the Ts65Dn mouse, we disclose evidence herein that 5-HT 6 receptor antagonists may alleviate the cognitive deficits observed in human subjects suffering from DS. Species within the claimed genus of 5-HT6 receptor antagonists restored the cognitive function of Ts65Dn mice almost to the level of control mice as demonstrated by an improved ability to differentiate between a familiar object in a familiar location and a novel object in a novel location. Consequently, the data disclosed herein support the claimed use of 5-HT 6 receptor antagonists for the treatment of cognitive deficits associated with DS.
(FR)
L'invention concerne des méthodes de traitement du syndrome de Down et d'amélioration de la fonction cognitive d'un patient présentant une déficience intellectuelle. On utilise des antagonistes du récepteur 5-HT6 (5-hydroxytryptamine sous-récepteur 6) pour améliorer la cognition d'un patient atteint du syndrome de Down (DS). Au moyen d'un modèle de souris de DS, la souris Ts65Dn, on a démontré que les antagonistes du récepteur 5-HT6 peuvent atténuer les déficits cognitifs observés chez des sujets humains atteints de DS. Une espèce se situant dans le genre revendiqué des antagonistes du récepteur 5-HT6 a restauré la fonction cognitive de plusieurs souris Ts65Dn pratiquement au niveau des souris témoins comme l'a démontré l'aptitude améliorée à faire la différence entre un objet familier dans un lieu familier et un nouvel objet dans un nouveau lieu. Par conséquent, les données présentées dans cette demande soutiennent l'utilisation revendiquée des antagonistes du récepteur 5-HT6 pour le traitement des déficits cognitifs associés à DS.
Also published as
Latest bibliographic data on file with the International Bureau